NasdaqGM - Delayed Quote USD

TransMedics Group, Inc. (TMDX)

129.98 +1.21 (+0.94%)
At close: May 10 at 4:00 PM EDT
130.00 +0.02 (+0.02%)
After hours: May 10 at 7:30 PM EDT
Loading Chart for TMDX
DELL
  • Previous Close 128.77
  • Open 130.26
  • Bid 129.53 x 100
  • Ask 130.02 x 200
  • Day's Range 128.57 - 131.58
  • 52 Week Range 36.42 - 132.96
  • Volume 663,688
  • Avg. Volume 927,291
  • Market Cap (intraday) 4.281B
  • Beta (5Y Monthly) 1.87
  • PE Ratio (TTM) --
  • EPS (TTM) -0.34
  • Earnings Date Aug 1, 2024 - Aug 5, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 119.20

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

www.transmedics.com

584

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TMDX

Performance Overview: TMDX

Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TMDX
64.68%
S&P 500
9.49%

1-Year Return

TMDX
72.25%
S&P 500
26.79%

3-Year Return

TMDX
436.22%
S&P 500
23.39%

5-Year Return

TMDX
416.00%
S&P 500
81.93%

Compare To: TMDX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TMDX

Valuation Measures

Annual
As of 5/10/2024
  • Market Cap

    4.28B

  • Enterprise Value

    4.45B

  • Trailing P/E

    --

  • Forward P/E

    3.33k

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    14.50

  • Price/Book (mrq)

    26.85

  • Enterprise Value/Revenue

    10.33

  • Enterprise Value/EBITDA

    -323.89

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -3.43%

  • Return on Assets (ttm)

    1.85%

  • Return on Equity (ttm)

    -5.79%

  • Revenue (ttm)

    296.92M

  • Net Income Avi to Common (ttm)

    -10.2M

  • Diluted EPS (ttm)

    -0.34

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    350.22M

  • Total Debt/Equity (mrq)

    323.71%

  • Levered Free Cash Flow (ttm)

    -238.06M

Research Analysis: TMDX

Company Insights: TMDX

Research Reports: TMDX

People Also Watch